Suppliers / Jubilant Generics

Jubilant Generics

India 855 employees Updated 9 July 2026

Jubilant Generics is an API and finished-dose manufacturer based in India. It appears in 166 regulatory filings across 10 regulators, without an active US DMF or CEP on file. Its filings concentrate with US FDA, Health Canada and MINSA (CR). Its GMP standing is certified by MHRA (UK), US FDA and NAFDAC (NG), among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 2 February 2024 as VAI. Customs aggregates show $36.7M of exports covering 1,283 molecules to 44 destinations in 2025.

0
active US DMFs
0
valid CEPs
5
registered plants 1 with an FDA FEI number
166
filings across 10 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 2 February 2024 VAI US FDA
  • 1 August 2022 OAI US FDA
  • 12 March 2021 OAI US FDA
  • 6 November 2019 OAI US FDA
  • 23 March 2017 NAI US FDA
  • 8 April 2016 VAI US FDA
  • 13 March 2015 VAI US FDA
  • 1 March 2013 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Uttarakhand, United Arab Emirates Not on file
Roorkee, United Arab Emirates Not on file
UTTARAKHAND, India Not on file
HARIDWAR, India Not on file
Roorkee, India 3006895982

What they file, and where

Molecule Regulators Docs
Risperidone SFDA (Saudi Arabia) 2
Solifenacin Succinate SFDA (Saudi Arabia) 2
Aripiprazole SFDA (Saudi Arabia) 1
Deferasirox SFDA (Saudi Arabia) 1
Escitalopram SFDA (Saudi Arabia) 1
Esomeprazole SFDA (Saudi Arabia) 1
Irbesartan SFDA (Saudi Arabia) 1
Lacosamide SFDA (Saudi Arabia) 1
Olanzapine SFDA (Saudi Arabia) 1
Quetiapine SFDA (Saudi Arabia) 1
Show all 13 molecules on file
Tadalafil SFDA (Saudi Arabia) 1
Valsartan SFDA (Saudi Arabia) 1
Zolmitriptan SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Azithromycin finished dose Celecoxib finished dose Citalopram finished dose Escitalopram API Felodipine finished dose Indomethacin finished dose Itraconazole finished dose Lacosamide API Olanzapine API Olmesartan Medoxomil finished dose Risperidone API Solifenacin API
Show 7 more molecule pages
Tizanidine finished dose Zolmitriptan API Valsartan API Quetiapine API Esomeprazole API Tadalafil API Irbesartan API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 95 1
Health Canada 32 None
MINSA (CR) 14 None
CDSCO (India) 7 None
EDE (AE) 6 None
NMRC (NA) 5 None
MHRA (UK) None 1
NAFDAC (NG) None 1
EMA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $3.7M 20
2025 Not reported $36.7M 44
2024 Not reported $33.5M 35
2023 Not reported $37.6M 39

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Jubilant Generics comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 10 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 2 February 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts